EUVIMEDEUVIMED entdecken
Crossref

Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation

Wenqi Li, Jing Liu, Ran Jiao, Zhigang Liu, Tiantian Zhang, Dan Chai, Lingxin Meng, Zhongyi Yang, Yuming Liu, Xiaoting Gu, Xiaohe Li, Cheng Yang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Wenqi Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, Ch…. Hauptthemen laut MEDLINE: Fibrosis, Azetidines, Sulfonamides, Fibroblasts. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Higher Education Discipline Innovation Project, Nankai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac fibrosis is characterized by the over-proliferation, over-transdifferentiation and over-deposition of extracellular matrix (ECM) of cardiac fibroblasts (CFs). Cardiac sympathetic activation is one of the leading causes of myocardial fibrosis. Meanwhile, cardiac fibrosis is often together with cardiac inflammation, which accelerates fibrosis by mediating inflammatory cytokines secretion. Recently, the Janus kinase/signal transducer and activator of transcription (JAK/STAT3) signaling pathway has been confirmed by its vital role during the progression of cardiac fibrosis. Thus, JAK/STAT3 signaling pathway is thought to be a potential therapeutic target for cardiac fibrosis. Baricitinib (BR), a novel JAK1/2 inhibitor, has been reported excellent effects of anti-fibrosis in multiple fibrotic diseases. However, little is known about whether and how BR ameliorates cardiac fibrosis caused by chronic sympathetic activation. Isoproterenol (ISO), a β-Adrenergic receptor (β-AR) nonselective agonist, was used to modulate chronic sympathetic activation in mice. As expected, our results proved that BR ameliorated ISO-induced cardiac dysfunction. Meanwhile, BR attenuated ISO-induced cardiac fibrosis and cardiac inflammation in mice. Moreover, BR also inhibited ISO-induced cardiac fibroblasts activation and macrophages pro-inflammatory secretion. As for mechanism studies, BR reduced ISO-induced cardiac fibroblasts by JAK2/STAT3 and PI3K/Akt signaling, while reduced ISO-induced macrophages pro-inflammatory secretion by JAK1/STAT3 and NF-κB signaling. In summary, BR alleviates cardiac fibrosis and inflammation caused by chronic sympathetic activation. The underlying mechanism involves BR-mediated suppression of JAK1/2/STAT3, PI3K/Akt and NF-κB signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrosisAzetidinesSulfonamidesFibroblastsPurinesPyrazolesMice, Inbred C57BLAnimalsMaleMiceSignal TransductionSTAT3 Transcription FactorMyocardiumIsoproterenolCells, CulturedAnti-Inflammatory AgentsNF-kappa BInflammationCytokinesHumansSympathetic Nervous System

Stichwörter der Autor:innen

BaricitinibCardiac fibrosisCardiac inflammationJAK/STAT3β-Adrenergic receptor

Substanzen

baricitinibAzetidinesSulfonamidesPurinesPyrazolesSTAT3 Transcription FactorIsoproterenolAnti-Inflammatory AgentsNF-kappa BCytokines

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China.
  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China; Tianjin Key Laboratory of Molecular Drug Research, International…

Förderung

  • National Natural Science Foundation of China
  • Higher Education Discipline Innovation Project
  • Nankai University

Zitieren

APA

Li, W., Liu, J., Jiao, R., Liu, Z., Zhang, T., Chai, D., Meng, L., Yang, Z., Liu, Y., Gu, X., Li, X., & Yang, C. (2024). Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112894

Vancouver

Li W, Liu J, Jiao R, Liu Z, Zhang T, Chai D, et al. Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112894

BibTeX
@article{Li2024,
  author = {Li, Wenqi and Liu, Jing and Jiao, Ran and Liu, Zhigang and Zhang, Tiantian and Chai, Dan and Meng, Lingxin and Yang, Zhongyi and Liu, Yuming and Gu, Xiaoting and Li, Xiaohe and Yang, Cheng},
  title = {Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112894}
}
Kostenlos starten →